Company Encyclopedia
View More
name
Shouyao Holdings
688197.SH
Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of pharmaceutical drugs in China. The company offers products for various indications, such as non-small cell lung cancer, lymphoma, hepatocellular carcinoma; pancreatic, breast, ovarian, and thyroid cancer; leukemia; and other diseases, such as diabetes. Shouyao Holdings (Beijing) Co., LTD.
3.051 T
688197.SHMarket value -Rank by Market Cap -/-

Financial Score

29/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking196/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-27.29%E
    • Profit Margin-9651.06%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-46.84%E
    • Net Profit YoY1.32%C
    • Total Assets YoY-22.64%E
    • Net Assets YoY-24.01%E
  • Cash ScoreD
    • Cash Flow Margin-1.04%D
    • OCF YoY-46.84%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio14.11%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shouyao Holdings plans to seek Hong Kong listing

    Shouyao Holdings plans to seek Hong Kong listing

    marketscreener·
    SH
    688197
    -0.85%
    marketscreener·
    SH
    688197
    -0.85%

    Shouyao Holdings: RET inhibitor Sotorasib tablets (SY-5007) new drug application has been accepted

    Shouyao Holdings announced that its self-developed RET inhibitor Sotorasib tablets (SY-5007) have been accepted for new drug application by the National Medical Products Administration. This drug is suitable for patients with locally advanced or metastatic non-small cell lung cancer with RET gene fusion positivity, showing significant efficacy and good safety, and is expected to provide new treatment options for patients

    Zhitong·
    SH
    688197
    -0.85%
    Zhitong·
    SH
    688197
    -0.85%

    Zhitong A-share lock-up release overview | September 23

    On September 23, a total of 6 listed companies had their restricted shares unlocked, with a total market value of approximately 6.569 billion yuan. The specific situation of the restricted shares unlocked today is as follows: Stock Abbreviation Stock Code Restricted Share Type Unlocked Shares Shanghai Airport 600009 Additional Issuance A Shares Original Shareholders' Allocation Listed 12.8 million HUALU-HENGSHENG 600426 Equity Incentive Restricted Circulation 280,000 CETC Digital 600850 Additional Issuance A Shares Legal Person Allocation Listed 81.107 million Apex 603383 Equity Incentive Restricted Circulation 162,000 Funshine Culture 300860 Equity Incentive Restricted Circulation 19,900 Shouyao Holdings 688197 6,491.6 million

    Zhitong·
    SZ
    300860
    -2.62%
    SH
    603383
    -1.14%
    SH
    688197
    -0.85%
    Zhitong·
    SZ
    300860
    -2.62%
    SH
    603383
    -1.14%
    SH
    688197
    -0.85%

    Shouyao Holdings: Net profit loss of 104 million yuan in the first half of 2025

    Shouyao Holdings announced that the operating income in the first half of 2025 is 2 million yuan, a year-on-year decrease of 47.37%. The net profit attributable to shareholders of the listed company is -104 million yuan, compared to -103 million yuan in the same period last year. The proportion of R&D investment to operating income is 5,408.49%, an increase of 2,590.03 percentage points

    Zhitong·
    SH
    688197
    -0.85%
    Zhitong·
    SH
    688197
    -0.85%

    The three major A-share indices of the Shanghai and Shenzhen markets rose by 0.6% to 2.8% in the first half of the day, with brokerage and innovative drug concept stocks gaining

    Today, the three major A-share indices performed strongly, with the SSE Index rising 0.6% to 3686 points, the Shenzhen Index rising 1.5% to 11518 points, and the ChiNext Index rising 2.8% to 2476 points. Brokerage stocks and innovative drug concept stocks performed prominently, with Guosheng Finance hitting the daily limit, and Shouyao Holdings and Haisco also reaching the daily limit. The central parity rate of the RMB against the USD was adjusted to 7.1350. The performance of domestic bank stocks was poor, with China Construction Bank and Industrial and Commercial Bank of China slightly declining

    AASTOCKS·
    SZ
    002653
    -2.16%
    SH
    688197
    -0.85%
    SH
    000001
    +0.04%
    AASTOCKS·
    SZ
    002653
    -2.16%
    SH
    688197
    -0.85%
    SH
    000001
    +0.04%
    © 2025 Longbridge｜Disclaimer